Neurocrine Biosciences Patent-Cliff Exposure & CMS Drug Spending Portfolio
Neurocrine Biosciences (San Diego, CA): 6 reconciled FDA prescription therapies, $2.56B 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | San Diego, CA |
| Reconciled FDA Portfolio Therapies | 6 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2035-01-01 |
| 2024 CMS Total Public Spend | $2.56B |
| 2024 Medicare Part D Spend | $1.97B |
| 2024 Medicaid Spend | $591.3M |
| California HCAI SB 17 Filings | 4 WAC filings (max 17.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.